US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

29.14

+0.43071.50%

Post-market: 29.170.0298+0.10%16:10 EDT

Volume:1K

Turnover:29.61K

Market Cap:2.62M

PE:- -

High:29.31

Open:29.30

Low:29.14

Close:28.71

52wk High:29.31

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:1.28

T/O Rate:1.12%

Dividend:0.92

Dividend Rate:3.15%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Press Release: Celcuity Appoints David Gryska to Its Board of Directors

Verastem announces data from analysis of Phase 2 RAMP 201 trial

Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo

BICO folds Cellenion into SCIENION to sharpen precision biotech focus

Nanobiotix taps veteran biotech CFO Arnd Christ to steer next growth phase

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Mizuho biotech analysts hold an analyst/industry conference call

JPMorgan SMid biotech analysts hold an analyst/industry conference call

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

Veeva supporting transformation of medicine through AI, Barron’s reports

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

RYUK-IL C&S pivots to biotech and pet markets with sweeping charter changes

Corvus announces initiation of Phase 1b clinical trial of soquelitinib

Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today?

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Satellos announces enrollment completed for BASECAMP

Citi Downgrades Moderna Stock after 222% Rally, Calls Oncology Expectations “Unrealistic”

3 Australian Biotech Stocks With Up To 77% Fair Value Upside

Simply Wall St.

Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/NVIB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":29.1392,"timestamp":1790971200000,"preClose":28.7085,"halted":0,"volume":1011,"hourTrading":{"tag":"盘后","latestPrice":29.169,"preClose":29.1392,"latestTime":"16:10 EDT","volume":6,"amount":174.8352,"timestamp":1790971804945,"change":0.0298,"changeRate":0.001023,"amplitude":0},"delay":0,"changeRate":0.015002525384467948,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.4307,"latestTime":"10-02 16:00:00 EDT","open":29.3,"high":29.31,"low":29.1392,"amount":29609,"amplitude":0.005949,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.7085,"nav":29.11,"aum":2619962.27,"dividendRate":0.031511,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.169,"preClose":29.1392,"latestTime":"16:10 EDT","volume":6,"amount":174.8352,"timestamp":1790971804945,"change":0.0298,"changeRate":0.001023,"amplitude":0},"volumeRatio":1.282669145427962},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.282669145427962,"shares":90001,"dividePrice":0.9182,"high":29.31,"amplitude":0.005949,"preClose":28.7085,"low":29.1392,"week52Low":24.54,"pbRate":"--","week52High":29.31,"institutionHeld":0,"latestPrice":29.1392,"eps":0,"divideRate":0.031511,"volume":1011,"delay":0,"ttmEps":0,"open":29.3,"prevYearClose":25,"prevWeekClose":28.0966,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":28.0966,"twentyDayClose":28.4889},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672591712","title":"Candel Therapeutics to Present at the SITC 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2672591712","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672591712?lang=en_us&edition=fundamental","pubTime":"2026-10-02 21:00","pubTimestamp":1790946000,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Oct.  02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3373820/0/en/candel-therapeutics-to-present-at-the-sitc-2026-annual-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOAT","MEDX","BK4121","IDNA","CADL","BK4080","SEA","GDOC","NVIB","BK1541","LU1880383366.USD","IE00B12V2V27.USD","IE00BYTNYN87.SGD","IE0003795394.USD","LU1880383440.USD","BK4109","01308","IE00BYQNZ168.SGD","DNA","IE0003851619.USD","BK1103","HYLG","BK4139","SG9999011746.SGD","BK4231","BK4539","SITC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672116477","title":"Press Release: Celcuity Appoints David Gryska to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2672116477","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672116477?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:00","pubTimestamp":1790942400,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tu","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IEIH","CELC","RSPH","BK4588","BK4555","BBP","GDOC","BK4099","BK4585","03160","IDNA","HYLG","TM","SYNB","NVIB","BK4139","BK4604","IBB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672005719","title":"Verastem announces data from analysis of Phase 2 RAMP 201 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2672005719","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672005719?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:35","pubTimestamp":1790940914,"startTime":"0","endTime":"0","summary":"Verastem (VSTM) Oncology announced data from a new molecular profiling and tumor biomarker analysis of the Phase 2 RAMP 201 clinical trial of avuto...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verastem-announces-data-from-analysis-of-phase-2-ramp-201-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verastem-announces-data-from-analysis-of-phase-2-ramp-201-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VSTM","IDNA","MEDX","HYLG","BK4139","NVIB","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672107715","title":"Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo","url":"https://stock-news.laohu8.com/highlight/detail?id=2672107715","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672107715?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:55","pubTimestamp":1790934913,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) announced a clinical trial collaboration agreement with Daiichi Sankyo (DSNKY) and AstraZeneca (AZN) to evaluate ivonesc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-enters-trial-collaboration-with-astrazeneca-daiichi-sankyo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-enters-trial-collaboration-with-astrazeneca-daiichi-sankyo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DSNKY","GDOC","IDNA","LU2462157665.USD","LU2456880835.USD","LU2468319806.SGD","LU1829250122.USD","LU0029864427.USD","BK4585","LU0310800379.SGD","BK4139","LU2237443622.USD","LU0889565916.HKD","IE00B3T34201.USD","BK4539","LU0708994859.HKD","LU0128525929.USD","LU2237443895.HKD","LU2236285917.USD","BK4007","LU1267930573.SGD","BK4568","AZN","LU2237443978.SGD","LU2237443549.SGD","SMMT","LU2237443382.USD","AZNH","MEDX","LU0320765992.SGD","LENZ","BK4588","LU2417539215.USD","HYLG","LU0289739699.SGD","LU2089984988.USD","LU2488822045.USD","NVIB","LU0432979614.USD","LU2237443465.HKD","LU0058720904.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672991794","title":"BICO folds Cellenion into SCIENION to sharpen precision biotech focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2672991794","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672991794?lang=en_us&edition=fundamental","pubTime":"2026-10-02 13:32","pubTimestamp":1790919176,"startTime":"0","endTime":"0","summary":"BICO Group AB Class B ( ($SE:BICO) ) has issued an announcement. BICO Group AB has completed the integration of single-cell specialist Cellenion in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bico-folds-cellenion-into-scienion-to-sharpen-precision-biotech-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bico-folds-cellenion-into-scienion-to-sharpen-precision-biotech-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","LU0210637038.USD","LU1861220207.SGD","LU2177674079.SGD","LU0532188223.SGD","IE0034224299.USD","SG9999013478.USD","SG9999005177.SGD","BK4220","BK4554","LU2008162690.USD","BK4585","LU0516423174.USD","LU2543165471.USD","SGXZ58947870.SGD","LU2152927971.USD","LU2065171311.SGD","BK4581","LU0572940350.SGD","LU1242518857.USD","SG9999002406.SGD","LU2125910849.SGD","LU0251143029.SGD","LU0441851309.USD","LU0261945553.USD","LU0499858438.USD","NVIB","SG9999014484.SGD","SG9999006266.SGD","SG9999013460.SGD","LU0516422440.USD","BK4085","BK4503","LU0737861269.HKD","SG9999013486.USD","LU0175139822.USD","XBIX","LU0499858602.USD","LU0072462343.USD","LU0589944569.HKD","SE","LU0048573645.USD","BK4588","LU0289960550.SGD","LU1861217088.USD","LU0345775950.USD","LU0516422952.EUR","LU2360107671.USD","FDNI","SG9999002620.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672629967","title":"Nanobiotix taps veteran biotech CFO Arnd Christ to steer next growth phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2672629967","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672629967?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:37","pubTimestamp":1790887025,"startTime":"0","endTime":"0","summary":"The latest update is out from Nanobiotix ( ($FR:NANO) ). Nanobiotix is a late‑stage French biotechnology company developing physics‑based therapeut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nanobiotix-taps-veteran-biotech-cfo-arnd-christ-to-steer-next-growth-phase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nanobiotix-taps-veteran-biotech-cfo-arnd-christ-to-steer-next-growth-phase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","XT","FWD","LNGR","BK4585","NVIB","BK4588","BBP","FHLC","JDOC","NANO","DARP","IBB","IEIH","SYNB","AGNG","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672764016","title":"Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672764016","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672764016?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:05","pubTimestamp":1790885100,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Oct.  01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3373386/0/en/mineralys-therapeutics-announces-presentation-of-lorundrostat-data-at-american-heart-association-hypertension-scientific-sessions-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","LENZ","BK4139","IDNA","BK4117","BK4539","AFG","NVIB","GDOC","MEDX","BK4007","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672761479","title":"Mizuho biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2672761479","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672761479?lang=en_us&edition=fundamental","pubTime":"2026-10-02 03:00","pubTimestamp":1790881217,"startTime":"0","endTime":"0","summary":"Biotech AnaLyst Syed, along with the Biotech Research Team, discuss Vaxcyte (PCVX), ahead of VAX-31 Ph3 OPUS-1 readout this October, as well as BBI...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XBI","IE0009354923.USD","BK4581","BK4585","PCVX","BK4588","XBIX","LU0053671581.USD","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672662237","title":"JPMorgan SMid biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2672662237","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672662237?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:50","pubTimestamp":1790873411,"startTime":"0","endTime":"0","summary":"SMid Biotechnology Analysts Cheng and Medeiros discuss their view on Kymera Therapeutics’s (KYMR) STATS readout in atopic dermatitis on an Analyst/...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jpmorgan-smid-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jpmorgan-smid-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","JPMO","NVIB","XLF","XBIX","LU0971096721.USD","LU0943347566.SGD","IYG","IYF","LU0265550946.USD","IE00B3S45H60.SGD","LU0320765489.SGD","KBWB","LU1917777945.USD","LU0820562030.AUD","JPM","LU0211326755.USD","LU0106831901.USD","LU0345769631.USD","TRUF","LU2505996509.AUD","IXG","UYG","FTXO","LU2168563687.JPY","LU2168564222.USD","LU1244550577.SGD","LU2357627491.SGD","JPO","LU2054465674.USD","LU1064131342.USD","IE000BZT7R73.USD","BK4139","LU2552382132.HKD","IE00BJTD4V19.USD","LU0256863902.USD","IE00BFXG1179.USD","PGF","TFNS","VFH","SG9999002224.SGD","KYMR","LU0234572021.USD","FNCL","BK4207","LU2236285917.USD","IE00BN8TJ469.HKD","LU2213496289.HKD","BK4585","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672750336","title":"AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2672750336","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672750336?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:02","pubTimestamp":1790859720,"startTime":"0","endTime":"0","summary":"Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC programOCALA, Fla., Oct.  01,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372985/29489/en/aim-immunotech-spotlights-growing-attention-around-ampligen-pancreatic-cancer-strategy-as-duripanc-advances-toward-topline-data.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","HYLG","GDOC","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672579387","title":"Veeva supporting transformation of medicine through AI, Barron’s reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2672579387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672579387?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:55","pubTimestamp":1790859332,"startTime":"0","endTime":"0","summary":"AI holds the promise to accelerate drug development, optimize clinical trials, and bring lifesaving therapies to market faster, and Veeva (VEEV) Sy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veeva-supporting-transformation-of-medicine-through-ai-barrons-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veeva-supporting-transformation-of-medicine-through-ai-barrons-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VTHR","BK4613","BK4504","BK4585","LU0170899867.USD","FBT","NVIB","ARTY","BK4167","LU1989764748.USD","QTOC","CHAT","LFSC","AIPO","LU0289739699.SGD","LU0058720904.USD","HYLG","GDOC","AGIX","MEDX","BK4588","BK4534","BMED","EKG","IDNA","LU0006306889.USD","LGHT","VEEV","LU0106261372.USD","BK4528","LU1989764664.SGD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672759490","title":"Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2672759490","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672759490?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:45","pubTimestamp":1790851500,"startTime":"0","endTime":"0","summary":"- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALT","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372706/0/en/kailera-therapeutics-presents-new-clinical-data-at-easd-2026-annual-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","OZEM","JDOC","BK4139","NVIB","HYLG","IDNA","GDOC","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672739201","title":"RYUK-IL C&S pivots to biotech and pet markets with sweeping charter changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2672739201","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672739201?lang=en_us&edition=fundamental","pubTime":"2026-10-01 11:12","pubTimestamp":1790824358,"startTime":"0","endTime":"0","summary":"RYUK-IL C&S., Ltd. ( ($KR:191410) ) has provided an announcement. RYUK-IL C&S., Ltd. shareholders approved a partial amendment of the Articles of I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ryuk-il-cs-pivots-to-biotech-and-pet-markets-with-sweeping-charter-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ryuk-il-cs-pivots-to-biotech-and-pet-markets-with-sweeping-charter-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672782978","title":"Corvus announces initiation of Phase 1b clinical trial of soquelitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2672782978","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672782978?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:10","pubTimestamp":1790799031,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals (CRVS) announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corvus-announces-initiation-of-phase-1b-clinical-trial-of-soquelitinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corvus-announces-initiation-of-phase-1b-clinical-trial-of-soquelitinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVS","BK4139","NVIB","HYLG","BK4568","GDOC","MEDX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671207502","title":"Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2671207502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671207502?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:14","pubTimestamp":1790774085,"startTime":"0","endTime":"0","summary":"Connect Biopharma stock rallied over 98% after the company announced new clinical trial data for rademikibart.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-penny-stock-connect-biopharma-cntb-up-98-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-penny-stock-connect-biopharma-cntb-up-98-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["82843","YINN","02843","ASHS","GDOC","YANG","HYLG","FXP","CHAU","82823","02823","NVIB","XPP","MEDX","BK4139","KCAI","YXI","KBA","82822","KWEB","ASHR","CWEB","FLCH","CNTB","IDNA","02822"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671253201","title":"Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2671253201","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671253201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:00","pubTimestamp":1790769600,"startTime":"0","endTime":"0","summary":"REVTORPYK (gedatolisib)   REVTORPYK (gedatolisib) vial and box  REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371842/0/en/celcuity-announces-that-revtorpyk-gedatolisib-is-now-commercially-available-in-the-united-states.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","ALT","BK4599","IDNA","SRET","HR","BK4225","BK4585","LABU","UBCP","BK4139","GDOC","BK4203","NVIB","LU1878469433.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671726206","title":"Satellos announces enrollment completed for BASECAMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2671726206","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671726206?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:15","pubTimestamp":1790766924,"startTime":"0","endTime":"0","summary":"Satellos (MSLE) Bioscience announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/satellos-announces-enrollment-completed-for-basecamp-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/satellos-announces-enrollment-completed-for-basecamp-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4139","IDNA","MSLE","NVIB","GDOC","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671206085","title":"Citi Downgrades Moderna Stock after 222% Rally, Calls Oncology Expectations “Unrealistic”","url":"https://stock-news.laohu8.com/highlight/detail?id=2671206085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671206085?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:15","pubTimestamp":1790766915,"startTime":"0","endTime":"0","summary":"Citigroup downgraded Moderna, Inc. ($MRNA) from Neutral/High Risk to Sell/High Risk after the biotech stock’s sharp two-month rally, arguing that o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/citi-downgrades-moderna-stock-after-222-rally-calls-oncology-expectations-unrealistic?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/citi-downgrades-moderna-stock-after-222-rally-calls-oncology-expectations-unrealistic?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","WDNA","MRNA","BK4548","BK4532","BK4501","BK4585","MRNX","BK4568","LGHT","NVIB","MRNY","BK4551","IDNA","XBIX","BK4534","BK4139","BK4533","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672738443","title":"3 Australian Biotech Stocks With Up To 77% Fair Value Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2672738443","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672738443?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:20","pubTimestamp":1790763656,"startTime":"0","endTime":"0","summary":"Australia’s inflation rate sitting at 4% and interest rates at a 15 year high of 4.6% are squeezing many growth stories. Yet that pressure also pushes investors toward companies with solid balance sheets and clear funding runways. That matters for Australian biotechnology stocks, where capital access can make or break a breakthrough. This article highlights three listed biotech opportunities screened for financial resilience and reasonable value.\nThe three biotech stocks covered below are a...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QFN.AU","BK4585","IMLC.AU","MYX.AU","BK7096","NVIB","XBI","OZR.AU","IIGF.AU","STW.AU","BK4588","BBOZ.AU","BK7508","XKO.AU","IOZ.AU","IISV.AU","SLF.AU","VLS.AU","ZYAU.AU","CUV.AU","XAO.AU","OZF.AU","BEAR.AU","DACE.AU","GEAR.AU","GIVE.AU","QRE.AU","BK4581","XJO.AU","XBIX","BK7067","VAP.AU","EIGA.AU","VAS.AU","E200.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671203699","title":"Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671203699","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671203699?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:10","pubTimestamp":1790763034,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-reports-results-from-phase-3-asc40-304-ole-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-reports-results-from-phase-3-asc40-304-ole-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","BK4139","MEDX","SGMT","NVIB","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}